Specify a stock or a cryptocurrency in the search bar to get a summary
Allovir Inc
ALVRAllovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts. Address: 1100 Winter Street, Waltham, MA, United States, 02451
Analytics
WallStreet Target Price
0.98 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ALVR
Dividend Analytics ALVR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALVR
Stock Valuation ALVR
Financials ALVR
Results | 2019 | Dynamics |